Is the mortality rate of patients with small cell lung cancer high?

Is the mortality rate of patients with small cell lung cancer high? Small cell lung cancer is similar to other cancers. There are many causes of the disease. Human intervention is ineffective and the disease is cruel and difficult to treat. Therefore, in daily life, if you have a cough, it is appropriate to choose to seek medical treatment in time. Today, let's find out together, is the mortality rate of patients with small cell lung cancer high?

Small cell carcinoma is a pathological type of lung cancer. This type of cancer is more malignant, so the survival time is relatively short and the prognosis is relatively poor. The specific survival time may be related to factors such as the severity of the tumor and physical fitness. You can actively treat it first to relieve the pain. The survival period depends on the patient's quality in all aspects, such as the patient's mood, physical fitness, the location and growth rate of the tumor, the treatment process, etc., which will affect the patient's survival period. It cannot be generalized. As long as active and reasonable treatment is given, there is hope.

Small cell lung cancer (SCLC) is an invasive disease, accounting for about 15% of all lung cancers. It has a low degree of differentiation, a high degree of malignancy, and a short doubling time (i.e., it progresses very quickly). Without chemoradiotherapy, the prognosis is very poor, with an average of about 3-6 months. However, another characteristic of small cells is that they are very sensitive to chemoradiotherapy, that is, the treatment effect of chemoradiotherapy is very good, and the initial objective remission rate is much higher than that of other lung cancers. Therefore, standardized chemoradiotherapy can greatly improve the survival time of patients. The third characteristic of small cell lung cancer is based on the good effect of initial chemoradiotherapy, that is, the late recurrence (progression) rate is high, so the overall situation is not optimistic, with a 5-year (or more) survival rate of only about 6%. In other words, the total survival of most patients after chemoradiotherapy is between 0.5 and 5 years.